+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Evidence–Based Respiratory Medicine. with CD–ROM. Evidence–Based Medicine

  • ID: 2221632
  • Book
  • 608 Pages
  • John Wiley and Sons Ltd
1 of 4
Compiled by specialists from the Cochrane Collaboration Airways Management Group,Evidence–based Respiratory Medicine is the first major evidence–based text in adult respiratory medicine.

Providing a comprehensive summary of the best treatments for the most important respiratory diseases, some of the world′s leading physicians review the evidence for a broad range of treatments using evidence–based principles. Essential information is presented in an easy–to–understand format, with the most important clinical implications summarised in each chapter.

Evidence–based Respiratory Medicine tackles the big clinical questions in diagnosis and treatment, presenting treatment options which take into account the individual patient′s needs.

Evidence–Based Series: Evidence–based Respiratory Medicine, part of the acclaimed series BMJ Evidence–based medicine textbooks that have revolutionised clinical medicine literature, comes with a fully searchable CD–ROM of the whole text.

Note: Product cover images may vary from those shown
2 of 4

Acknowledgement to Cochrane Library.

1 Practising evidence–based respiratory medicine.

1.1 Introduction.

1.2 Diagnostic strategies.

1.2.1 Presenting symptoms.

1.2.2 Lung function testing.

1.2.3 Chest radiographic and CT patterns.

1.2.4 Diagnostic strategies in pulmonary embolism: an evidence–based approach.

1.2.5 Screening for lung cancer.

1.3 Therapeutics: general issues.

1.3.1 Adherence and self–management.

1.3.2 Corticosteroid–induced osteoporosis.

1.3.3 Helping people to stop smoking.

2 Asthma.

2.1 Acute exacerbations.

2.2 Chronic therapy: beta–agonists short–acting, long–acting beta2–agonists.

2.3 Inhaled corticosteroids in the treatment of asthma.

2.4 Anti–leukotrienes.

2.5 Asthma education.

.2.6 Non–pharmacological and complementary interventions to manage asthma.

2.7 Difficult asthma.

2.8 Novel therapies in asthma: long–acting beta2–agonists/inhaled corticosteroids.

3 Chronic obstructive pulmonary disease.

3.1 Chronic obstructive pulmonary disease acute exacerbations.

3.2 Anticholinergic bronchodilators in chronic obstructive pulmonary disease therapy.

3.3 Inhaled corticosteroids in chronic obstructive pulmonary disease.

3.4 Combination of inhaled corticosteroids and long–acting beta2–agonists in chronic obstructive pulmonary disease.

3.5 Systemic corticosteroids in stable chronic obstructive pulmonary disease.

3.6 Lung volume reduction.

4 Infection.

4.1 Bronchitis and sinusitis.

4.2 Community–acquired pneumonia.

4.3 Pulmonary tuberculosis.

4.4 Influenza: vaccination and treatment.

4.5 Bronchiectasis.

4.6 Adult cystic fibrosis.

4.7 Antibiotics in chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis.

5 Respiratory failure/sleep disordered breathing.

5.1 Respiratory rehabilitation.

5.2 Non–invasive ventilation in acute respiratory failure.

5.3 Non–invasive positive pressure ventilation in stable patients with chronic obstructive pulmonary disease. What is the evidence?

5.4 The treatment of the obstructive sleep apnoea hypopnoea syndrome.

5.5 Long–term oxygen therapy for chronic respiratory failure in chronic obstructive pulmonary disease.

6 Diffuse lung disease / pleural disease / thromboembolism.

6.1 Diffuse lung disease.

6.1.1 The treatment of cryptogenic fibrosing alveolitis.

6.1.2 Evidence–based approach to treatment of sarcoidosis.

6.1.3 Hypersensitivity pneumonitis.

6.2 Pleural disease.

6.3 Therapy of pulmonary thromboembolism: an evidence–based approach.

6.4 Pulmonary hypertension.


Note: Product cover images may vary from those shown
3 of 4


4 of 4
Peter G. Gibson
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/2221632